Last reviewed · How we verify
NCT06707259
Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHL
Recruiting now
Phase 1
Last updated 20 November 2025
What this trial tests
Phase 1 trial testing anti-CD19 IL10/IL15 CAR-NK in B-cell Non Hodgkin Lymphoma in 24 participants. Currently enrolling.
Timeline
1 December 2024
Primary endpoint
1 December 2026
1 December 2026
1 December 2027
Quick facts
| Lead sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 1 December 2024 |
| Primary completion | 1 December 2026 |
| Estimated completion | 1 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- anti-CD19 IL10/IL15 CAR-NK — full drug profile →
Conditions studied
- B-cell Non Hodgkin Lymphoma — all drugs for B-cell Non Hodgkin Lymphoma →
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Who can join
Adults 18 to 75, any sex, with B-cell Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the safety and effectiveness of cord blood-derived IL-10/IL-15 CD19-CAR NK in patients with B-cell non-Hodgkin's lymphoma
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy.
Dos Reis FD, Saidani Y, Martín-Rubio P, Sanz-Pamplona R, et al · · 2025 · cited 11× · PMID 40519903 · DOI 10.3389/fimmu.2025.1603757 -
Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies.
Bock AM, Epperla N. · · 2025 · cited 8× · PMID 40597378 · DOI 10.1186/s13045-025-01702-5 -
Chimeric antigen receptor therapies: Development, design, and implementation.
Lee MJ, Cichocki F, Miller JS. · · 2025 · cited 5× · PMID 40220909 · DOI 10.1016/j.jaci.2025.04.005 -
Natural killer cells in adoptive cell therapy: current landscape of genetic engineering strategies.
Burón M, Etxebarria A, Álvarez M, Romayor I, et al · · 2025 · cited 4× · PMID 40996824 · DOI 10.1080/2162402x.2025.2563099 -
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them.
Legato L, Bisio M, Fasano F, Benevolo Savelli C, et al · · 2025 · cited 3× · PMID 40981226 · DOI 10.3390/mps8050108 -
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment.
Budagova T, Efremova A, Maiak M, Goldshtein D. · · 2025 · cited 1× · PMID 41369346 · DOI 10.3390/cells14231858 -
Chimeric antigen receptor natural killer (CAR-NK) cells: from preclinical promise to clinical reality in cancer immunotherapy.
Cochran HC, Ghobadi KA, Ghobadi A. · · 2025 · PMID 41186143 · DOI 10.1080/1750743x.2025.2582464
Verify or expand the search:
- PubMed search for NCT06707259
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for B-cell Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT06392477 — A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgki · Phase 1 · recruiting
- NCT06508775 — Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies · NA · recruiting
- NCT05991388 — A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma · Phase 2, PHASE3 · recruiting
- NCT05702853 — Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL · Phase 1, PHASE2 · recruiting
- NCT05338931 — Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma · Phase 1, PHASE2 · recruiting
Other Second Affiliated Hospital, School of Medicine, Zhejiang University trials
Trials by the same sponsor.
- NCT07445152 — Research on Construction and Verification of Multimodal Medical Imaging Large Model · not yet recruiting
- NCT06775665 — A Real-World Study on Hypertrophic Cardiomyopathy in Chinese Population · not yet recruiting
- NCT07533422 — Rescue Reatment of Helicobacter Pylori Based on Fecal Antimicrobial Resistance Gene Testing · NA · not yet recruiting
- NCT07487285 — A Non-inferiority Study of Laser Combined With Ultrasonic Debridement Therapy (LCUDT) Versus Manual Combined With Ultras · NA · not yet recruiting
- NCT07505186 — Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT06707259 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Second Affiliated Hospital, School of Medicine, Zhejiang University
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06707259.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing